CJC-1295 (No DAC) in Australia: The Research Guide

CJC-1295 (No DAC) in Australia, in short

CJC-1295 (No DAC) is a synthetic growth hormone releasing hormone (GHRH) analogue studied in laboratory research for how it influences the pituitary release of growth hormone. The No DAC version omits the Drug Affinity Complex, so it is short acting with a half life measured in minutes, which is why researchers often pair it with ipamorelin in study protocols. In Australia it is supplied strictly for laboratory and research use and is not TGA approved for human consumption.

What is CJC-1295 (No DAC)?

CJC-1295 is a modified fragment of natural growth hormone releasing hormone. The research literature also refers to it as Modified GRF 1-29, because it is based on the first 29 amino acids of GHRH with a small number of substitutions that improve its stability against enzymatic breakdown. It belongs to the family of compounds known as GHRH analogues.

The phrase No DAC is the key detail. DAC stands for Drug Affinity Complex, a molecular addition that lets a peptide bind to blood albumin and circulate for days. CJC-1295 with DAC is long acting. CJC-1295 No DAC, sometimes written CJC-1295 without DAC, has that complex removed, so it acts over a much shorter window. This short profile is precisely why it features so heavily in controlled research designs, where a brief and defined pulse of activity is easier to model than a multi day one.

• GHRH analogue based on the GRF 1-29 sequence
• No DAC means no albumin binding complex, so a short half life
• Studied for how it interacts with the GHRH receptor on the pituitary
• Commonly appears in research alongside a GH secretagogue such as ipamorelin

How CJC-1295 is studied and its proposed mechanism

In preclinical research, CJC-1295 is investigated as a GHRH receptor agonist. The proposed mechanism is straightforward in outline. Natural GHRH signals the anterior pituitary to release growth hormone in pulses. CJC-1295, as a stabilised GHRH analogue, is studied for how it engages that same receptor pathway and influences the amplitude of those pulses in laboratory models.

Because the No DAC form is cleared quickly, researchers describe it as producing a short, defined signal rather than a sustained elevation. This is often contrasted with the DAC form in study notes, where the DAC version is characterised as producing a longer bleed of activity. Neither description is a claim about outcomes in people. They are observations from research on receptor engagement and hormone release dynamics.

Key research areas for GHRH analogues

GHRH analogues as a class have been examined across several research directions. The points below describe what has been studied in models and in the literature, not benefits to any reader.

• Growth hormone release dynamics: how a GHRH analogue affects the timing and size of GH pulses in preclinical models
• Downstream signalling: research interest in the GH to IGF-1 axis as a measured readout
• Receptor pharmacology: characterising binding at the GHRH receptor and comparing modified sequences
• Half life engineering: comparing No DAC and DAC constructs to understand how albumin binding changes duration of action
• Combination research: studying a GHRH analogue together with a separate GH secretagogue pathway

None of these research areas establishes a therapeutic use, and CJC-1295 is not an approved therapy in Australia. They simply describe why the compound is of interest to laboratories working on endocrine signalling.

CJC-1295 and ipamorelin: why they are studied together

The most common pairing in the research community is CJC-1295 (No DAC) with ipamorelin. The reason is that the two compounds are studied for acting on different pathways. CJC-1295 is a GHRH analogue that engages the GHRH receptor. Ipamorelin is a selective growth hormone secretagogue that is studied at a separate receptor, the ghrelin or GH secretagogue receptor.

Because the two research targets are distinct, laboratories frequently examine them in combination to understand whether engaging both pathways at once produces a different release profile than either alone. Ipamorelin is also noted in the literature for its selectivity, being studied as one of the GH secretagogues with limited off-target effect on other hormones in models. This is why the CJC-1295 ipamorelin combination is one of the most referenced research pairings in the peptide space.

No DAC versus DAC: choosing for a research design

The single most important variable when researchers select a CJC-1295 construct is the presence or absence of the Drug Affinity Complex, because it changes the entire time course of activity.

• CJC-1295 No DAC (Modified GRF 1-29): short half life, activity measured in minutes, studied for producing brief pulse-like signals, often combined with ipamorelin
• CJC-1295 with DAC: albumin binding extends the half life to days, studied for producing sustained elevation, dosed far less frequently in research protocols

Researchers choosing between them are usually deciding whether their study calls for a short defined pulse or a long steady signal. That design question, not any personal outcome, drives the selection. NovaPeptides lists the No DAC form clearly so laboratories can match the construct to the study.

CJC-1295 in Australia: status and buying from a transparent supplier

In Australia, CJC-1295 is handled as a research compound. It is not TGA approved for human consumption, and peptides of this type are generally treated as prescription-only or Schedule 4 substances in the therapeutic context. That is why a reputable supplier will only ever offer CJC-1295 for laboratory and research use, and will not provide personal dosing guidance. We follow that line strictly.

When you buy CJC-1295 in Australia for research, the thing that separates a serious supplier from a risky one is verifiable quality. Every batch NovaPeptides supplies carries an independent Novagen Laboratories Certificate of Analysis with a unique key you can verify, so you are not taking identity and purity on trust. NovaPeptides is Australian owned and has supplied research peptides to Australians for over 3 years, with discreet tracked shipping and same day Gold Coast dispatch on orders placed in time.

• Australian owned supplier with over 3 years serving Australian researchers
• Independent Novagen Laboratories COA on every batch, verifiable by unique key
• Discreet, tracked shipping across Australia
• Same day Gold Coast dispatch on eligible orders
• Supplied strictly for laboratory and research use, never for human consumption

Reading a CJC-1295 COA

A Certificate of Analysis is the document that tells you what is actually in the vial. For CJC-1295 (No DAC), a meaningful COA identifies the peptide, reports its purity, and is tied to a specific batch rather than being a generic marketing sheet. This is why NovaPeptides attaches an independent Novagen Laboratories COA, with a unique verifiable key, to every batch.

• Peptide identity confirmed, typically by mass spectrometry
• Purity reported, commonly by HPLC, for the specific batch
• A batch or lot number that matches the vial you received
• A unique key that lets you independently verify the certificate rather than trusting a screenshot

If you are new to reading these documents, the identity and purity figures plus a matching batch number are the core things to confirm. The verifiable key is what turns a claim into something you can actually check.

Research handling notes

As a peptide supplied for laboratory use, CJC-1295 (No DAC) is handled by researchers under standard laboratory practice. General reference points from the literature include that lyophilised peptides are typically stored cold and kept away from light and moisture, and that reconstituted material has a shorter usable window than the sealed lyophilised powder. These are laboratory handling references, not instructions for any human use.

Frequently asked questions

Related guides